Madhumita is the Principal Scientist, Target Discovery at MelliCell. In the core, Madhumita is highly motivated basic research scientist who strongly believes in hypothesis-driven science that lead to novel discovery. Madhumita has 16+ years of academic experience and training, which spans over an area of Population and Human Molecular Genetics to Developmental Biology. Madhumita’s career sums up as a Scientist who’s passionate about both basic and discovery research.

Dr. Bickel is an Associate Professor and the Division Chief at UT Southwestern Medical Center. He is the Distinguished Chair in Internal Medicine. He graduated from UT Southwestern Medical school and did his residency and a fellowship at Harvard Medical School/Massachusetts General Hospital.

Dr. Bikman is an Associate Professor of Physiology and Developmental Biology at Brigham Young University. He is an expert on insulin resistance and obesity with a focus on the molecular mechanisms of disease within adipocytes. He advises MelliCell in the selection of therapeutic targets and strategies for safe and sustained weight loss.

He is a biomedical engineer with wide-ranging experience in device development, tissue engineering, and synthetic biology, with a recent focus on design and fabrication of organ-on-a-chip microfluidics with integrated sensing capabilities.

Aaron is committed to tackling intractable problems in healthcare, working to identify quantifiable metrics to map the spectrum between health and disease.

Pareesha is a highly motivated student at Boston University studying Biochemistry & Molecular Biology.

Dr. Prakash is a drug discovery professional with over 20 years of experience in the pharmaceutical and biotechnology industry. He has brought countless new chemical entities to the clinical testing stage including an A1 receptor agonist for glaucoma and the first poly (ADP-ribose) polymerase inhibitor to enter clinical trials.

He currently holds over 40 US and international patents in the fields of new chemical entities, investigational drug processes, pharmacology, disease treatments, and inventor of clinical candidates.

Prakash currently serves as MelliCell's own Director of Medicinal Chemistry and plays a vital role in identifying, designing, and synthesizing potential drug candidates for our mission to cure type two diabetes.

Prince is an entrepreneur with passion for solving healthcare issues that span the value chain. His focus on the life sciences drove him to receive a doctorate in pharmacology from MCPHS University. Prince had his first industry experience at Johnson & Johnson where he learned first-hand the drug development & discovery process. He is a US Army veteran and received an MBA from the University of Southern California.

Sunny Oworah is a dedicated Brandeis University alumnus with an M.Sc. in Business Analytics, complemented by an MBA and a B.Sc. in Microbiology. His blend of analytical and scientific expertise allows him to tackle complex business challenges with precision. Proficient in tools like SQL, Python, and Tableau, Sunny excels at transforming complex datasets into actionable insights. His detail-oriented mindset and problem-solving skills have been key in uncovering trends and optimizing business strategies. Sunny is eager to apply his data-driven approach to drive impactful results in any organization.

Dr. Peterson is an Assistant Professor of Physiology at the Mayo Clinic. His research focus is diabetes drug discovery through chemical screening.His track record includes development of a novel class of drugs now in Phase I clinical trials. He advises MelliCell in high-throughput screening and lead development.

Cross-trained in biology and engineering, Ben brings interdisciplinary expertise and management experience to lead our scientific and technology development efforts. Ben has been pursuing a cure for diabetes since his parents’ diagnosis over 20 years ago and is an inventor of MelliCell’s core technology.

Nicole is an experienced laboratory technician that graduated from the University of Rochester. Her educational background is in Biomedical Engineering with a concentration in Cell and Tissue Engineering as well as a minor in Chemical Engineering. She finished her Master of Science. in biomedical engineering at Boston University.

Nicole currently plays an essential role in MelliCell laboratory operations.

Todd Spalding is a seasoned legal executive with over two decades of experience in the biopharmaceutical industry. Currently, he serves as Senior Vice President and Deputy General Counsel at AstraZeneca, based in Boston, Massachusetts. Previously, he held key roles at Alexion Pharmaceuticals, where he led intellectual property strategy, and at Bristol-Myers Squibb. Todd began his career as an associate at Foley & Lardner LLP. He holds a J.D. from William & Mary and an M.S. in Biotechnology from Johns Hopkins University.

Dr. Stanford is an Associate Professor of Medicine and Pediatrics who practices and teaches at Massachusetts General Hospital (MGH)/ Harvard Medical School (HMS) as one of the first fellowship-trained obesity medicine physicians worldwide. She is among the most highly cited obesity medicine physician-scientists, with over 200 peer-reviewed publications. Dr. Stanford received her BS and MPH from Emory University as an MLK Scholar, her MD from the Medical College of Georgia School of Medicine as a Stoney Scholar, her MPA from the Harvard Kennedy School of Government as a Zuckerman Fellow in the Harvard Center for Public Leadership and her executive MBA as a merit-based scholarship recipient from the Quantic School of Business and Technology. She completed her Obesity Medicine & Nutrition Fellowship at MGH/HMS after completing her internal medicine and pediatrics residency at the University of South Carolina. She has served as a health communications fellow at the Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. Upon completing her MPH, she received the Gold Congressional Award, the highest honor Congress bestows upon America’s youth.

Gianna Tamilio is currently a Data Science Intern at MelliCell, where she utilizes her expertise in Python and SQL to contribute to significant data-driven projects. Alongside her internship, Gianna is pursuing a Master of Science in Computational and Applied Mathematics at the University of Massachusetts Lowell after earning her Bachelor of Science in Mathematics. She also brings a multifaceted skill set as a part-time Group Fitness Instructor at UMass Lowell and as an experienced Assistant at Expert Electrology and Laser, showcasing her strong organizational and technical abilities.

Dr. Williams is an Associate Physician at Brigham and Women's Hospital and an Assistant Professor of Medicine at Harvard Medical School. His research is focused on understanding the interplay of environmental factors and genetics and their contribution to cardiometabolic diseases.

Andreas is an effective leader and experienced professional with the proven ability to turn innovative ideas and technology into mission-critical corporate core competencies. 20 years of experience developing scientific computational and information management solutions in pre- and post-IPO corporate environments. Proven track record of inventions, scientific publications, and s uccessful grant applications. Expert in AI/machine learning, data science, deep learning, mathematical modeling, quantitative analysis, computational chemistry, bioinformatics, genomics, statistics and software development. Tenacious problem solver with a strong conviction that ideas are worthless unless reduced to practice.

Todd C. Zion, Ph.D. is the Co-founder, President, and CEO of Akston Biosciences Corporation, which specializes in insulin engineering and has raised over $15 million to develop therapeutics for diabetes and oncology. Previously, he founded SmartCells, Inc., where he developed SmartInsulin, acquired by Merck and Co. for clinical trials. Dr. Zion holds a Ph.D. from MIT and a B.S. from Cornell, and he actively mentors at MIT and serves on several advisory boards.